ALT241115C5500
- 2.05
- 0.000.00%
Altimmune Newsroom
Executive Reshuffles: TWO, CYBR, PFG and ALT
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
Altimmune Third Quarter 2024 Earnings: Beats Expectations
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Altimmune's Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick Trucchio
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
Altimmune | 10-Q: Quarterly report
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Altimmune Appoints Gregory Weaver as CFO for Growth
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript Summary
Altimmune Analyst Ratings
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $5,000
Express News | Altimmune Q3 Revenue USD 5 Thousand Vs. IBES Estimate USD 800
Express News | Altimmune Q3 Operating Expenses USD 24.772 Million
Press Release: Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update